Lilly and EVA Pharma announce regulatory approval and release of locally manufactured insulin in Egypt
The Egyptian Medicines Authority approves insulin glargine injection produced by EVA Pharma (www.EVAPharma.com) through a partnership with Eli Lilly and Company (NYSE: LLY ). Launched in 2022, the collaboration aims to provide a sustainable supply of high-quality, affordable human insulin and analogue insulin to at least 1 million people living with type 1 and type 2 diabetes each year in low- and middle-income countries (LMICs). Most of them are in Africa.
This marks the first time EVA Pharma’s insulin drug product has received regulatory approval following the collaboration between Eli Lilly and Company (https://apo-opa.co/41xlg6K) will be announced in December 2022. Under the agreement, Eli Lilly has been supplying its insulin active pharmaceutical ingredients (APIs) to EVA Pharma at significantly reduced prices and is providing a free technology transfer that enables EVA Pharma to formulate, fill and complete insulin vials and cartridges.
Less than two years since its initial announcement, Evergreen has completed construction of a new biologics manufacturing facility, finalized the insulin formulation and stability testing process, worked with local regulatory authorities to obtain approval of insulin glargine injection, And launched the first batch of products to manufacture insulin medicines locally.
In addition, Evergreen Pharmaceuticals’ human insulin injection has also been submitted to local regulatory authorities for approval. Eli Lilly and Company and EVA Pharma continue to work with the World Health Organization (WHO) to ensure that locally produced human insulin injection is prequalified by the WHO. This World Health Organization prequalification will further ensure that the drugs produced by Yihua Pharmaceutical meet the high quality standards set by the World Health Organization.
“Eli Lilly has been at the forefront of diabetes care for more than a century, delivering innovative solutions that make people around the world live better,” said Ilya Yuffa, executive vice president and president of Eli Lilly International. Wonderful.” “We are with EVA Pharma. The collaboration furthers our commitment to delivering sustainable and accessible medicines around the world. We will continue to work with health systems and industry stakeholders around the world to address systemic barriers to health care and expand equitable, affordable access. access to medicines to change more lives. ”
“Localization of essential medicines is key to driving equitable access to healthcare,” said Riad Armanious, CEO of EVA Pharma. “It will take bold collaborations, cutting-edge innovation and technology-driven manufacturing to turn this vision into a reality. We have partnered with Eli Our partnership shows that when we push boundaries together, anything is possible. This is just the beginning – we have the potential to impact more than one million lives in 56 countries every year and make a real difference to people living with diabetes.”
The collaboration is part of Eli Lilly’s 30×30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030.
Recently, Eli Lilly and EVA Pharma expanded their collaboration, announcing (https://apo-opa.co/3ZCUhUJ) Eli Lilly and Company will license certain baricitinib manufacturing technologies, enabling EVA Pharma to manufacture and deliver treatments for various immune diseases in 56 low- and middle-income countries in Africa.
Distributed by APO Group on behalf of EVA Pharma.
Media Contact:
Karin glared.
mendelek_karine@lilly.com
+971553408407
(Eli Lilly Media)
Michael Chapa
czapar_michael_c@lilly.com
317-617-0983
(Eli Lilly Investor)
Ahmed Elwa
ahmed.ellewa@evapharma.com
+20-1000-053-643
(Yihe Medical Media)
About Eli Lilly:
Eli Lilly and Company is a pharmaceutical company dedicated to transforming science into treatments that make life better for people around the world. We’ve been making life-changing discoveries for nearly 150 years, and today our medicines are helping tens of millions of people around the world. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s greatest health challenges: Redefining diabetes care; Treating obesity and reducing its most devastating long-term effects; Advancing Fighting Alzheimer’s disease; providing solutions to some of the most serious immune system diseases; and transforming the most difficult-to-treat cancers into manageable diseases. Every step we take toward a healthier world, we’re motivated by one thing: making life better for millions of people. This includes delivering innovative clinical trials that reflect the diversity of the world and working to ensure our medicines are accessible and affordable. To learn more, please visit Eli Lilly and Company and https://apo-opa.co/41yTHKjor follow us on Facebook (https://apo-opa.co/4fpu7dM), Instagram (https://apo-opa.co/4011yOv) and LinkedIn (https://apo-opa.co/41GZ5ej). Li Lai
About Yihe Pharmaceutical:
EVA Pharma is committed to improving access to affordable, quality medicines around the world, focusing on three core pillars: innovation, development and sustainable access. The company leverages cutting-edge technology from its two research centers to bring unprecedented capabilities to the Middle East and Africa, ranging from artificial intelligence predictions to mRNA research and development of bioproducts.
EVA Pharma’s team of 5,000 professionals produces over 1 million healthcare products daily at four state-of-the-art manufacturing facilities that are internationally recognized for innovation and have received approval from multiple regulatory agencies.
Guided by a relentless drive to ensure sustainable access to pressing but unmet disease areas, the company’s product portfolio focuses on twelve therapeutic areas: anti-infectious, metabolic health, bone, neuroscience, oncology, respiratory, Gynecology, Urology and Andrology, Paediatrics, Ophthalmology, Gastroenterology, Family Medicine to meet local and international needs.
EVA Pharma is one of the fastest growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence and operations in more than 70 countries around the world.
For more information, please visit: www.EVAPharma.com&https://apo-opa.co/4gimRSu Or follow us on Facebook (https://apo-opa.co/3VJmyYz), LinkedIn (https://apo-opa.co/41KhFlE)&Instagram (https://apo-opa.co/3VHxS7F).
Cautionary Statement Regarding Forward-Looking Statements:
This press release contains forward-looking statements regarding (as such term is defined in the Private Securities Litigation Reform Act of 1995) Eli Lilly and EVA Pharma Collaboration and reflect Eli Lilly’s current beliefs and expectations. However, there can be no assurance that Lilly’s collaboration with EVA Pharma will achieve Lilly’s objectives or that Lilly will execute its strategy as planned. For further discussion of the risks and uncertainties related to Eli Lilly’s business that could cause actual results to differ from Eli Lilly’s expectations, please see Eli Lilly’s filings on Form 10-K and Form 10-Q with the U.S. Securities and Exchange Commission . Eli Lilly assumes no obligation to update forward-looking statements to reflect events occurring after the date of this release, except as required by law.
